Compound News and Research

RSS

QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), is presenting a poster today on positive clinical data from its recent mechanism of action study in mild cognitive impaired (MCI) patients at the International Congress on Alzheimer's Disease (ICAD 2010).

15 Jul 2010

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NovaBay Pharmaceuticals, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay's first-in-class Aganocide family of compounds, which are designed to fight infections without causing drug resistance.

15 Jul 2010

Activities of TAT fully consolidated into Geron

Geron Corporation today announced that the activities of TA Therapeutics, its joint venture with Hong Kong University of Science and Technology, are being fully consolidated into Geron.

15 Jul 2010

No harmful levels of benzene, other compounds emitted from natural gas sites: BSEEC study

The Barnett Shale Energy Education Council today released the results of its air quality testing project which showed there are no harmful levels of benzene and other compounds being emitted from natural gas sites tested in Fort Worth and Arlington City Council District 2.

15 Jul 2010

Pre-clinical study results of EVP-0015962 presented at AAICAD 2010

EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2010 International Conference on Alzheimer's Disease results from its proprietary gamma-secretase modulator pre-clinical study. In a transgenic mouse model, EnVivo's EVP-0015962 reduced amyloid plaque buildup which is believed to be a cause of Alzheimer's disease, reversed behavioral deficits and reduced brain inflammation associated with Alzheimer's disease.

15 Jul 2010

New Cystex Liquid Cranberry Complex with Proantinox reduces incidence of UTIs in women: Study

A new study being published in the journal Urology shows that Proantinox, a proprietary cranberry-based blend used successfully in hospitals and long-term care facilities as UTI-Stat, and now available directly to consumers as new Cystex Liquid Cranberry Complex with Proantinox, is safe and effective in significantly reducing the incidence of UTIs in women at risk for recurring infections.

15 Jul 2010

Evotec to acquire DeveloGen

Evotec AG today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to €14m in shares plus performance-related deferred payments (earn-out).

15 Jul 2010

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

The leukemia stem cell-the root cause of all acute leukemias- represents a small population of cells in patients that are difficult to eliminate with standard treatments available today. Though current chemotherapy can produce temporary remission in leukemia survivors, they remain at risk of experiencing a recurrence and dying from the disease.

15 Jul 2010

Insight into inner functional mechanisms of new bacterial infection target

In any battle, sizing up one's opponent is a critical first step. For researchers fighting a bacterial infection, that means assessing every nook and cranny of the malicious microorganism and identifying which ones to attack.

14 Jul 2010

ACRO releases statement regarding proposed privacy rule from HHS

The Association of Clinical Research Organization is pleased that the proposed privacy rule from Department of Health and Human Services strikes an appropriate balance between the critical needs of researchers for access to health information and the desire to protect the privacy of individual's health records.

14 Jul 2010

EntreMed announces publication of preclinical data for ENMD-2076

EntreMed, Inc., today announced the publication of preclinical data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor, which demonstrated significant activity against multiple myeloma cell lines and in MM models in vivo. Results of the study, conducted by EntreMed's collaborator, Sherif Farag, M.D., Ph.D., and colleagues at the Indiana University School of Medicine, were published in the on-line version of the British Journal of Haematology on June 15, 2010 and are scheduled to be published in print in the August 1, 2010 issue.

13 Jul 2010

Gene mutation that causes auditory neuropathy identified

Researchers have identified a gene mutation that causes a rare form of hearing loss known as auditory neuropathy, according to U-M Medical School scientists.

13 Jul 2010

Researchers discover gene mutation that causes auditory neuropathy

Researchers have identified a gene mutation that causes a rare form of hearing loss known as auditory neuropathy, according to U-M Medical School scientists. In the study published online today in the Proceedings of the National Academy of Sciences USA, U-M's Marci Lesperance, M.D., and Margit Burmeister, Ph.D. led a team of researchers who examined the DNA of individuals from the same large family afflicted with the disorder.

13 Jul 2010

Scientists receive $1.6M in new funding to advance healthcare research

University of Montreal scientists have received $1.6 in new funding to advance healthcare research over the next three years, as part of a Government of Canada announcement to support 31 research projects at 12 universities across the nation. Some $13 million in funding, from the Collaborative Health Research Projects program, will be awarded over three years to foster collaborations between scientists from the natural, engineering and health sciences.

13 Jul 2010

Rohto launches AFC Medirepair with Signum's compound Arazine in Japan

Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in Japan. Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs).

12 Jul 2010

Data shows potential health benefits of S-equol in relieving menopausal symptoms

The findings of a scientific conference examining the growing body of research and potential health benefits of S-equol were published this month in the Journal of Nutrition. Manuscripts based on presentations made at the conference, which was organized by the Life Sciences Research Office, reveal data that S-equol is a safe, natural and effective solution to providing relief of menopausal symptoms such as hot flashes and muscle discomfort.

9 Jul 2010

EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

Catalyst Pharmaceutical Partners, Inc. today announced that the European Patent Office (EPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a European patent for the use of vigabatrin for the prevention of addiction to opioids (e.g., oxycodone, hydrocodone) used in pain management.

9 Jul 2010

USF granted patent for cell transplantation procedure

The University of South Florida's Department of Neurosurgery and Brain Repair has been granted a patent for a cell transplantation procedure combining human umbilical cord blood cells and a sugar-alcohol compound called "mannitol" that may make a big difference in treating life-threatening neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and stroke, among others.

8 Jul 2010

Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program

Selvita sp. z o.o., from Krakow, Poland and Orion Corporation from Espoo, Finland (ORNBV) today announced that they have entered into a global collaboration to jointly develop and commercialize SEL103, Selvita's proprietary program for the treatment of Alzheimer's disease and other cognitive disorders. Selvita will be responsible for early research on the program and Orion will take over the pre-clinical and clinical development as well as further commercialization.

8 Jul 2010

Drug initiative granted rights to develop TB compounds for potential treatment of NTDs

The Drugs for Neglected Diseases Initiative now has the rights to "develop a class of potential anti-[tuberculosis] compounds" for the treatment of Chagas disease, African sleeping sickness and leishmaniasis, Reuters reports (Nebehay, 7/7).

8 Jul 2010

Compound News and Research

QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

Activities of TAT fully consolidated into Geron

No harmful levels of benzene, other compounds emitted from natural gas sites: BSEEC study

Pre-clinical study results of EVP-0015962 presented at AAICAD 2010

New Cystex Liquid Cranberry Complex with Proantinox reduces incidence of UTIs in women: Study

Evotec to acquire DeveloGen

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

Insight into inner functional mechanisms of new bacterial infection target

ACRO releases statement regarding proposed privacy rule from HHS

EntreMed announces publication of preclinical data for ENMD-2076

Gene mutation that causes auditory neuropathy identified

Researchers discover gene mutation that causes auditory neuropathy

Scientists receive $1.6M in new funding to advance healthcare research

Rohto launches AFC Medirepair with Signum's compound Arazine in Japan

Data shows potential health benefits of S-equol in relieving menopausal symptoms

EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

USF granted patent for cell transplantation procedure

Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program

Drug initiative granted rights to develop TB compounds for potential treatment of NTDs

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News